Simple and cost-effective cancer diagnosis in liquid biopsy through native tRNA sequencing
This project aims to validate a cost-effective Nano-tRNAseq method for quantifying tRNA abundances and modifications as novel cancer biomarkers, facilitating early detection and potential commercialization.
Projectdetails
Introduction
Transfer RNAs (tRNAs) are abundant, heavily-modified small non-coding RNAs that play a pivotal role in decoding genetic information, determining which transcripts are highly and poorly translated at a given moment. Dysregulation of tRNA abundances and tRNA modifications is a well-known feature in cancer cells, leading to enhanced translation of specific oncogenic proteins.
Background
Despite the well-established association between tRNA dysregulation and cancer progression and malignancy, tRNA abundances and their modifications are still not being used as diagnostic or prognostic markers for cancer detection or progression. This is mainly due to the lack of a simple, unbiased, and cost-effective method to quantify tRNA abundances and their modifications.
Methodology
Our laboratory has recently established Nano-tRNAseq, a pioneering method that can accurately quantify both tRNA abundances and tRNA modifications using native tRNA nanopore sequencing, for a fraction of the cost of next-generation sequencing-based approaches.
Technical Approach
By employing a proprietary Nano-tRNAseq nanopore library preparation protocol coupled with deep learning algorithms that will rapidly classify the nanopore current signals, we aim to establish a method that exploits tRNAs as novel biomarkers through the use of third generation sequencing technologies.
Initial Findings
We have initial evidence of how our approach can separate cancer from non-cancer samples and possibly be used to identify the tissue of origin.
Project Goals
In this project, we will fully validate our technological platform for the differential analysis of low-input RNA amounts in liquid biopsy samples.
Future Applications
We will initially apply our method in the cancer arena, expandable to many other indications, following the advice of key stakeholders contacted so far. The goal is to lay the basis for the transfer of our technology to the marketplace, including through the creation of a new start-up company.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 150.000 |
Totale projectbegroting | € 150.000 |
Tijdlijn
Startdatum | 1-1-2025 |
Einddatum | 30-6-2026 |
Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- FUNDACIO CENTRE DE REGULACIO GENOMICApenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Clone-based full-length RNA-seq for early diagnosis of cancerDeveloping a novel 3D clone-based RNA-seq technology to enhance detection of rare mutations and splicing in cancer cells for improved early diagnosis and personalized treatment strategies. | ERC Proof of... | € 150.000 | 2022 | Details |
Detecting epigenetic biomarkers in the blood for non-invasive precision oncologyDevelop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution. | ERC Starting... | € 1.500.000 | 2022 | Details |
Synthetic nucleic acid co-transcriptional networks as diagnostic and therapeutic toolsCO-TRANS-NET aims to create innovative synthetic nucleic acid units for simultaneous cancer diagnosis and therapy using cell-free transcription to enhance patient care. | ERC Starting... | € 1.499.750 | 2025 | Details |
Single-Clone Multi-omics Sequencing for Cancer DiagnosisDeveloping MultiCloneSeq, a cost-effective single-cell multi-omics sequencing tool, to enhance cancer diagnosis by profiling genetic mutations and RNA expression simultaneously. | ERC Proof of... | € 150.000 | 2023 | Details |
Multiplexed microRNA detection platform for early diagnosis and patient managementThe MiRACLE project aims to develop a cost-effective diagnostic platform for early disease detection by utilizing a novel optical sensing method to simultaneously detect individual micro-RNA molecules in bodily fluids. | ERC Proof of... | € 150.000 | 2024 | Details |
Clone-based full-length RNA-seq for early diagnosis of cancer
Developing a novel 3D clone-based RNA-seq technology to enhance detection of rare mutations and splicing in cancer cells for improved early diagnosis and personalized treatment strategies.
Detecting epigenetic biomarkers in the blood for non-invasive precision oncology
Develop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution.
Synthetic nucleic acid co-transcriptional networks as diagnostic and therapeutic tools
CO-TRANS-NET aims to create innovative synthetic nucleic acid units for simultaneous cancer diagnosis and therapy using cell-free transcription to enhance patient care.
Single-Clone Multi-omics Sequencing for Cancer Diagnosis
Developing MultiCloneSeq, a cost-effective single-cell multi-omics sequencing tool, to enhance cancer diagnosis by profiling genetic mutations and RNA expression simultaneously.
Multiplexed microRNA detection platform for early diagnosis and patient management
The MiRACLE project aims to develop a cost-effective diagnostic platform for early disease detection by utilizing a novel optical sensing method to simultaneously detect individual micro-RNA molecules in bodily fluids.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Versatile Amplification Method for Single-Molecule Detection in Liquid BiopsyVerSiLiB aims to develop an enzyme-free amplification platform for detecting proteins and nucleic acids in liquid biopsies, enhancing cancer management through novel affinity-mediated transport. | EIC Pathfinder | € 2.994.244 | 2022 | Details |
Best-in-class canceR dIaGnostic cHip for patient sTratification.The RUBYchip is a microfluidic liquid biopsy device that isolates and analyzes cancer cells from blood samples, enabling efficient and reliable monitoring of cancer progression. | EIC Accelerator | € 2.497.880 | 2022 | Details |
TraffikGene-Tx: Targeted Peptide Carriers for RNA DeliveryTraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs. | EIC Transition | € 2.498.963 | 2023 | Details |
DETACT - Detection of Enzymes and muTAtions for Cancer TreatmentCytura Therapeutics en ENPICOM ontwikkelen een innovatieve diagnostische assay voor vroege kankerdetectie door het meten van enzymactiviteit en mutatiepatronen in bloedcellen. | Mkb-innovati... | € 215.845 | 2019 | Details |
Versatile Amplification Method for Single-Molecule Detection in Liquid Biopsy
VerSiLiB aims to develop an enzyme-free amplification platform for detecting proteins and nucleic acids in liquid biopsies, enhancing cancer management through novel affinity-mediated transport.
Best-in-class canceR dIaGnostic cHip for patient sTratification.
The RUBYchip is a microfluidic liquid biopsy device that isolates and analyzes cancer cells from blood samples, enabling efficient and reliable monitoring of cancer progression.
TraffikGene-Tx: Targeted Peptide Carriers for RNA Delivery
TraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs.
DETACT - Detection of Enzymes and muTAtions for Cancer Treatment
Cytura Therapeutics en ENPICOM ontwikkelen een innovatieve diagnostische assay voor vroege kankerdetectie door het meten van enzymactiviteit en mutatiepatronen in bloedcellen.